Orum’s CEO to Present at BIO Investor Forum in San Francisco

Daejeon, South Korea, October 4, 2018 – Orum Therapeutics announced today that the company’s founder and Executive Officer SJ (Sung Joo) Lee, Ph.D. was invited to present a corporate overview at the 2018 BIO Investor Forum, being held October 17-18 in San Francisco. 

Conference Presentation Details:

When:   Wednesday, October 17, 2018 at 9:45 am PDT

Where:  The Westin St. Francis Hotel, San Francisco, California

Room:   Elizabethan D

To schedule a meeting with Orum, please submit a request through the conference one-on-one partnering system.

About BIO and the BIO Investor Forum

BIO, the Biotechnology Innovation Organization, is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

The BIO Investor Forum is an international biotechnology investor conference focused on early and established private companies as well as emerging public companies. The event features plenary sessions, business roundtables and therapeutic workshops, company presentations, and One-on-one Partnering™ meetings.

About Orum Therapeutics, Inc.

Orum Therapeutics is a private biotech company developing a new class of therapeutic antibodies to bring new medicines to patients with unmet medical needs. Orum leverages its unique cell penetrating antibody platform to inhibit drug targets undruggable by small molecule or current antibody therapeutics. In contrast to other approaches, Orum’s antibody platform can target specific cell types, is easily adaptable to target different cell types and different intracellular proteins, and does not require chemical modification. This provides new opportunities to treat severe genetic diseases and cancer.